Core Viewpoint - Guangyuyuan's subsidiary, Shanxi Guangyuyuan, has received a registration certificate for the non-prescription traditional Chinese medicine, An Gong Niu Huang Wan, from the Macao SAR government's drug regulatory authority, which will aid in expanding its overseas market presence [1] Group 1 - The registration application for An Gong Niu Huang Wan was submitted on May 7, 2025 [1] - The medicine is indicated for clearing heat and detoxifying, and its traditional production technique has been recognized as a national intangible cultural heritage [1] - The projected sales revenue for this product in the relevant market for 2024 is approximately 498.242 million yuan [1] Group 2 - The approval of An Gong Niu Huang Wan is expected to assist the company in expanding its international market reach [1] - The impact of this approval on the company's current performance is not expected to be significant [1]

Core Viewpoint - Guangyuyuan (600771.SH) has received a Traditional Chinese Medicine registration certificate for its product "An Gong Niu Huang Wan" from the Macao SAR government, marking a significant step in expanding its market presence in Macao [1] Group 1: Company Developments - Guangyuyuan's subsidiary, Shanxi Guangyuyuan National Medicine Co., Ltd., submitted the registration application for "An Gong Niu Huang Wan" on May 7, 2025 [1] - The product is recognized as a classic formula in traditional Chinese medicine, with historical roots tracing back to the Qing Dynasty [1] Group 2: Product Information - "An Gong Niu Huang Wan" is indicated for treating heat diseases, including high fever, convulsions, and various neurological conditions [1] - The traditional production technique of "An Gong Niu Huang Wan" has been included in the national intangible cultural heritage list, highlighting its cultural significance [1]

2025年12月24日，上海久诚律师事务所股票索赔律师许峰代理的广誉远（维权）（600771）虚假陈述投 资者索赔案再向太原市中级人民法院提交一次立案。（牛彬律师专栏） 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 2025年12月24日，上海久诚律师事务所股票索赔律师许峰代理的广誉远（维权）（600771）虚假陈述投 资者索赔案再向太原市中级人民法院提交一次立案。（牛彬律师专栏） 许峰律师代理的广誉远投资者索赔案已多次向法院提交立案，目前正在等待法院的下一步安排，律师团 队还在继续推进后续案件的立案工作，还在继续接受其他投资者的索赔委托。 2024年4月11日，广誉远公告收到证监会山西监管局《行政处罚决定书》，经查明，广誉远股份违法事 实如下： 许峰律师代理的广誉远投资者索赔案已多次向法院提交立案，目前正在等待法院的下一步安排，律师团 队还在继续推进后续案件的立案工作，还在继续接受其他投资者的索赔委托。 2024年4月11日，广誉远公告收到 ...

Core Viewpoint - The article discusses the ongoing legal actions against Guangyuyuan (stock code: 600771) for false statements made between 2016 and 2021, leading to investor claims for compensation due to misleading financial disclosures [1][2]. Group 1: Legal Proceedings - The law firm Shanghai Jiucheng, represented by lawyer Xu Feng, has submitted multiple claims to the Taiyuan Intermediate People's Court regarding investor compensation for Guangyuyuan [1]. - The law firm continues to accept claims from other investors who have suffered losses due to the company's misleading financial practices [1]. Group 2: Regulatory Findings - On April 11, 2024, Guangyuyuan received an administrative penalty decision from the Shanxi Regulatory Bureau of the China Securities Regulatory Commission, confirming violations related to the company's financial reporting [1]. - The company was found to have misrepresented its "buyout sales" model in annual reports from 2016 to 2021, including improper revenue recognition and incorrect handling of sales expenses [1]. Group 3: Investor Compensation Eligibility - Investors who purchased Guangyuyuan stock between March 21, 2017, and December 29, 2023, and sold or continued to hold the stock after December 29, 2023, are eligible to initiate compensation claims [2]. - The law firm has a history of successfully representing investors in similar cases, with nearly 200 stocks resulting in victories or settlements [2].

Core Viewpoint - The company has received approval for the registration of Banxia Xiexin Decoction Granules, which will enhance its product portfolio in traditional Chinese medicine [1][4]. Group 1: Drug Information - The drug is named Banxia Xiexin Decoction Granules, in granule form, with a specification equivalent to 27.77g of herbal slices per bag [1]. - It is classified as a Category 3.1 traditional Chinese medicine, based on ancient classic prescriptions [1]. - The drug's approval number is Guoyao Zhunzi C20250017, and it is produced by Shanxi Guangyuyuan National Medicine Co., Ltd [1]. Group 2: Market Context - The prescription for Banxia Xiexin Decoction Granules originates from Zhang Zhongjing's "Shanghan Lun" and is included in the first batch of the National Administration of Traditional Chinese Medicine's classic formula directory [2]. - The market for gastrointestinal traditional Chinese medicine, including this product, is projected to reach a total sales amount of 10.615 billion yuan in 2024, reflecting a year-on-year increase of 1.01% [2]. - Currently, no other companies have obtained the drug registration certificate for Banxia Xiexin Decoction Granules in China [2]. Group 3: Company Investment - The company has invested a total of 9.0266 million yuan in the research and development of this drug to date [3]. Group 4: Impact on the Company - The approval of Banxia Xiexin Decoction Granules will diversify the company's traditional Chinese medicine product offerings and create synergies with existing core products [4].

证券日报网讯 12月23日，广誉远在互动平台回答投资者提问时表示，公司目前有海南知了有方医疗科 技有限责任公司、海南知了有方互联网医院有限公司、海南知了有方远程医疗中心有限公司三家子公司 注册地在海南，并实质性运营，均正常享受当地相关政策。公司作为百年老字号中药企业，会持续关注 相关政策变化，结合现有业务情况，及时研判规划，持续为公司长期发展注入动力。 （文章来源：证券日报） ...

Core Viewpoint - Guangyuyuan (600771.SH) announced that its subsidiary, Shanxi Guangyuyuan Traditional Chinese Medicine Co., Ltd., has received the drug registration certificate for Banxia Xiexin Decoction Granules from the National Medical Products Administration [1] Company Summary - The Banxia Xiexin Decoction Granules are derived from the ancient prescription in Zhang Zhongjing's "Shanghan Lun" and are included in the first batch of the "Directory of Classic Ancient Formulas" published by the National Administration of Traditional Chinese Medicine [1] - The product is indicated for balancing cold and heat, resolving phlegm, and is used for symptoms of phlegm syndrome characterized by fullness without pain, vomiting, bowel sounds, and slight yellow greasy tongue coating [1]

Core Viewpoint - Guangyuyuan (600771.SH) announced that its subsidiary, Shanxi Guangyuyuan Traditional Chinese Medicine Co., Ltd., received the drug registration certificate for Banxia Xiexin Decoction Granules from the National Medical Products Administration [1] Company Summary - The product, Banxia Xiexin Decoction Granules, is derived from the ancient text "Shanghan Lun" by Zhang Zhongjing from the Han Dynasty and is included in the first batch of the "Directory of Classic Ancient Formulas" published by the National Administration of Traditional Chinese Medicine [1] - The function and indication of the product are to harmonize cold and heat, resolve phlegm, and alleviate fullness, specifically for symptoms of phlegm syndrome characterized by fullness without pain, vomiting, bowel sounds, and slight yellow greasy tongue coating [1]

Core Viewpoint - Guangyuyuan (600771) is actively expanding its product distribution by entering the "Tao Xiaopang" supermarket with its health liquor products "Qingchun Xiaopao" and "Lanbaoshi" [1] Group 1 - The company's entry into "Tao Xiaopang" supermarket is part of its normal strategic planning for the liquor business [1] - This initiative aims to enhance interaction between products and consumers through diversified sales channels and consumption scenarios [1] - The company reports that production, sales, and supply are all operating normally, ensuring timely market demand fulfillment [1]

Group 1 - The core announcement is that Guangyuyuan's subsidiary, Shanxi Guangyuyuan Traditional Chinese Medicine Co., Ltd., has received the drug registration certificate for Banxia Xiexin Decoction Granules from the National Medical Products Administration [1] - The formula for Banxia Xiexin Decoction Granules is derived from the Han Dynasty text "Shanghan Lun" by Zhang Zhongjing, indicating its historical significance in traditional Chinese medicine [1] - The product is indicated for the treatment of symptoms related to the imbalance of cold and heat, specifically for phlegm accumulation and gastrointestinal discomfort, characterized by fullness without pain, vomiting, and diarrhea [1]